Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Melanotan 2 UK: Complete Research Guide (2026)

Melanotan 2 UK: Complete Research Guide (2026) Melanotan 2 UK: Complete Research Guide (2026) Research Disclaimer: Melanotan 2 is sold for research and laboratory purposes only and is not intended for human use. This guide is for educational purposes for resea

By Recovery & Performance Peptides Editorial Team

Melanotan 2 UK: Complete Research Guide (2026)

Melanotan 2 UK: Complete Research Guide (2026)

Research Disclaimer: Melanotan 2 is sold for research and laboratory purposes only and is not intended for human use. This guide is for educational purposes for researchers and scientists only.

What is Melanotan 2 (MT-2)?

Melanotan 2 is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide hormone in the body. As a research compound, MT-2 has been the subject of scientific investigation since its development in the late 1980s at the University of Arizona. The peptide is designed to interact with melanocortin receptors, making it a valuable tool for studying melanogenesis, photoprotection, and various physiological processes.

The compound exists as a lyophilised (freeze-dried) powder and requires reconstitution with bacteriostatic water before use in laboratory settings. Researchers have utilised Melanotan 2 to investigate skin pigmentation mechanisms, UV protection pathways, and other endocrine functions.

Mechanism of Action: How Melanotan 2 Works

Melanotan 2 functions as a melanocortin receptor agonist, primarily targeting the melanocortin-1 receptor (MC1R) and melanocortin-4 receptor (MC4R). Understanding its mechanism is crucial for researchers working with this compound.

Melanocortin Receptor Agonism

The MC1R pathway is the primary mechanism through which MT-2 stimulates melanin production. When MT-2 binds to MC1R on melanocytes, it triggers intracellular signalling cascades that increase the production and distribution of eumelanin (dark pigment) and pheomelanin (red/yellow pigment). This receptor activation is what makes MT-2 valuable for studying skin pigmentation pathways.

The MC4R pathway involves the hypothalamus and is associated with appetite regulation and metabolic processes, which explains why researchers have investigated MT-2’s effects on food intake and energy homeostasis in laboratory models.

Melanin Production and UV Protection

Research has shown that Melanotan 2 stimulates melanin synthesis in a dose-dependent manner. The resulting increase in skin pigmentation provides researchers with a model system to study natural photoprotection mechanisms. Some studies have suggested that increased melanin levels may offer UV-absorbing properties, though human studies remain limited.

Skin Pigmentation Research

One of the primary applications of Melanotan 2 in research has been investigating the mechanisms of skin pigmentation. The compound’s ability to stimulate melanocytes has made it valuable for studying:

Melanin synthesis pathways and regulation

Melanocyte proliferation and differentiation

Pigmentation distribution across skin types

The relationship between receptor activation and pigment production

Published research has documented observable darkening of existing moles and the development of new pigmentation in individuals exposed to the compound during experimental settings. This makes MT-2 a useful research tool for understanding how the body regulates pigment production at the cellular level.

Sexual Function Research and Aphrodisiac Properties

Beyond pigmentation, researchers have investigated Melanotan 2’s effects on sexual function and arousal. The MC4R pathway involvement in the hypothalamus may influence libido through neuroendocrine mechanisms. Studies have documented improvements in erectile function and increased sexual motivation in research subjects, though the exact mechanisms require further investigation.

This aspect of MT-2 research has attracted scientific interest in the fields of sexual medicine and neuropharmacology, with researchers exploring how melanocortin signalling influences sexual behaviour and physiology.

Appetite Suppression and Metabolic Research

The MC4R agonism of Melanotan 2 has led researchers to investigate its potential effects on appetite regulation and food intake. The melanocortin system in the hypothalamus plays a critical role in energy homeostasis, and some research has suggested that MT-2 may influence satiety signals.

Studies have documented reduced appetite in research subjects following MT-2 administration, with some evidence of modest weight changes. This makes MT-2 a potentially valuable tool for researching the melanocortin system’s role in obesity and metabolic regulation.

Melanotan 1 vs Melanotan 2: Key Differences

Whilst both Melanotan 1 and Melanotan 2 are melanocortin receptor agonists, they differ in important ways:

Receptor Selectivity

Melanotan 1 (MT-1) is more selective for the MC1R pathway, making it primarily a pigmentation research compound. Melanotan 2, by contrast, has broader receptor activity, affecting both MC1R and MC4R. This broader activity profile is why MT-2 has been investigated for multiple physiological effects beyond simple pigmentation.

Duration of Action

MT-2 has a longer duration of action compared to MT-1, making it more suitable for sustained research investigations. This extended activity window has been documented in multiple research protocols.

Side Effect Profile

Due to its broader receptor activity, MT-2 produces a wider range of effects and reported side effects compared to MT-1. Researchers must account for these differences when designing protocols and selecting the appropriate compound for their investigation.

Research on UV Protection and Melanin Production

A key area of Melanotan 2 research involves understanding how increased melanin production relates to UV protection. Several published studies have explored:

The protective effects of MT-2-induced melanin against UVA and UVB radiation

Melanin’s role as an endogenous photoprotectant

How MT-2 stimulation might enhance the body’s natural sun defence mechanisms

The relationship between pigmentation levels and skin damage prevention

Research Disclaimer: These studies remain primarily investigational, and MT-2 should not be considered a replacement for conventional sun protection methods such as sunscreen.

Safety Profile and Reported Side Effects in Research

Like all research compounds, Melanotan 2 carries potential risks and documented side effects. Researchers must be aware of these when conducting investigations:

Common Reported Effects

Nausea: Often reported in the initial phases of administration, typically resolving with continued use

Facial flushing: Temporary reddening, particularly noticeable during the acute phase

Appetite suppression: As discussed, this may be intentional for metabolic research

Sexual arousal: Increased libido and genital sensitivity have been documented

Darkening of moles: Existing pigmented lesions may darken; careful monitoring is essential

Potential Serious Concerns

Mole monitoring: The ability of MT-2 to stimulate melanin production raises theoretical concerns about melanoma risk, though long-term epidemiological data is limited

Cardiovascular effects: Some research has suggested potential effects on blood pressure and heart rate; monitoring is recommended

Visual disturbances: Rare reports of changes in eye pigmentation and vision effects have been documented

Systemic effects: As a peptide hormone analogue, MT-2 may influence various endocrine pathways

Research Disclaimer: Melanotan 2 is a research compound with incomplete long-term safety data. Any research involving MT-2 should be conducted only by trained professionals in appropriate laboratory settings with proper medical oversight.

Dosing Protocols from Published Research

Dosing in published research varies based on investigational goals and administration route. Common protocols include:

Subcutaneous Administration

Most published research utilising MT-2 has employed subcutaneous injection. Typical dosing ranges from 0.5 mg to 2 mg per injection, administered at varying intervals depending on the research protocol. Some protocols use loading doses followed by maintenance dosing.

Dose-Response Relationships

Research has demonstrated dose-dependent effects, with higher doses producing more pronounced pigmentation changes and other effects. Individual response variation is significant, and genetic factors (particularly MC1R polymorphisms) influence individual sensitivity to MT-2.

Administration Schedules

Research protocols have varied widely, ranging from single-dose studies to multi-week dosing schedules. Some researchers have used daily administration, whilst others have employed every-other-day or weekly protocols depending on their investigational objectives.

Research Disclaimer: Dosing information is presented for educational understanding of published research only. Appropriate dosing for any specific research protocol should be determined by qualified researchers and institutional review boards.

Storage and Reconstitution: Practical Laboratory Considerations

Proper storage and handling of Melanotan 2 is essential for maintaining compound integrity and ensuring reliable research results.

Storage of Lyophilised Powder

Melanotan 2 is supplied as a lyophilised (freeze-dried) powder. For maximum stability:

Store in a cool, dark place away from direct sunlight

Keep away from moisture and humidity

Ideal storage temperature is 2-8°C (refrigerated) or room temperature (15-25°C) in airtight containers

Properly stored, the lyophilised powder remains stable for extended periods

Once reconstituted, solutions should be stored at 2-8°C and used within the timeframe recommended by the supplier

Reconstitution with Bacteriostatic Water

MT-2 requires reconstitution before use in most research applications:

Use sterile bacteriostatic water (sodium chloride 0.9% with benzyl alcohol) for reconstitution

Bacteriostatic water inhibits bacterial growth in the reconstituted solution

The reconstitution process should follow aseptic technique to prevent contamination

Standard reconstitution creates solutions of varying concentrations depending on research needs (typically 10 mg/mL)

Reconstituted solutions should be labelled with concentration, date of reconstitution, and expiration date

Sterility and Quality Assurance

Researchers should verify that their MT-2 supply includes certificates of analysis (COA) demonstrating:

Purity testing results

Sterility and endotoxin testing

Identity confirmation (HPLC or mass spectrometry)

Potency assays

UK Legal Status: Research Use Only

In the United Kingdom, Melanotan 2 occupies a specific regulatory position:

Research Exemption

MT-2 is not approved for human consumption or medical use in the UK. However, it is available for purchase and use strictly for research, scientific, and laboratory purposes. This exemption allows qualified researchers and institutions to conduct investigations with the compound.

Not Intended for Human Use

Critical Research Disclaimer: Melanotan 2 is explicitly not intended for human use outside of carefully controlled research settings. Any use for cosmetic purposes (self-tanning), performance enhancement, or non-research applications is outside the intended use and may violate regulations.

Supplier Responsibilities

Legitimate UK suppliers of Melanotan 2 for research explicitly state that the compound is for laboratory and research purposes only. Reputable suppliers provide documentation of purity and sterility, appropriate storage guidance, and clear legal disclaimers.

Researcher Obligations

Researchers in the UK using Melanotan 2 should:

Conduct work within institutional review frameworks

Maintain proper documentation of all research activities

Source compounds from reputable suppliers with proper certification

Follow all relevant health and safety regulations

Ensure ethical approval if the research involves any human subjects or tissues

UK Sourcing Guidance for Researchers

For UK-based researchers seeking Melanotan 2, several considerations are important:

Supplier Selection Criteria

When sourcing MT-2, researchers should prioritise suppliers who:

Provide certificates of analysis (COA) for all products

Conduct third-party purity testing

Offer sterility and endotoxin certification

Provide clear research-only disclaimers

Maintain professional laboratory standards

Offer appropriate storage and handling guidance

Have established reputations within the research community

Verification of Product Quality

Before commencing research with MT-2, verify:

That the compound matches the ordered specifications

That batch numbers are clearly documented

That expiration dates are noted

That all documentation is complete and accessible

That storage conditions match supplier recommendations

Documentation and Record Keeping

Proper research practice requires maintaining detailed records of:

Supplier information and batch details

Certificates of analysis for each batch used

Reconstitution dates and procedures

Storage and handling procedures

All research protocols and observations

Frequently Asked Questions About Melanotan 2

Q1: Is Melanotan 2 legal in the UK?

Melanotan 2 is legal to purchase and use for research and laboratory purposes in the UK. It is not approved for human consumption or cosmetic use outside of research settings.

Q2: How long does it take for Melanotan 2 to work?

In research settings, visible pigmentation effects typically begin within 3-5 days of starting administration, with maximum effects usually observed after 7-14 days of continued use.

Q3: What is the difference between Melanotan 1 and Melanotan 2?

MT-2 has broader receptor activity than MT-1, affecting both MC1R (pigmentation) and MC4R (appetite/sexual function) pathways. MT-2 also has a longer duration of action.

Q4: Does Melanotan 2 provide UV protection?

Research suggests that MT-2-induced melanin production may provide some photoprotective effects, but it should never be used as a replacement for conventional sun protection methods such as sunscreen.

Q5: What are the main side effects of Melanotan 2?

Commonly reported effects include nausea, facial flushing, appetite suppression, and increased sexual arousal. Researchers must carefully monitor for more serious potential effects, including mole darkening and cardiovascular changes.

Q6: How should Melanotan 2 be stored?

The lyophilised powder should be stored in a cool, dark place (2-8°C is ideal) away from moisture and light. Once reconstituted with bacteriostatic water, solutions should be refrigerated and used according to supplier guidelines.

Q7: Can Melanotan 2 increase melanoma risk?

This is an important research question. Whilst the ability of MT-2 to stimulate melanin production and darken moles raises theoretical concerns, comprehensive long-term epidemiological data on melanoma risk remains limited. Researchers using MT-2 must carefully monitor any pigmented lesions.

Q8: Where can I source high-quality Melanotan 2 in the UK?

Researchers should source MT-2 from reputable suppliers that provide certificates of analysis, purity testing, sterility certification, and clear research-only disclaimers. Established research chemical suppliers with professional standards are the appropriate source.

Q9: What makes a Melanotan 2 supplier reputable?

Reputable suppliers maintain third-party testing, provide comprehensive documentation, follow good manufacturing practices, offer customer support for researchers, and have established track records within the scientific community.

Q10: Is Melanotan 2 safe for research use?

Melanotan 2 carries documented risks and potential side effects. Research Disclaimer: MT-2 should only be used in controlled laboratory settings by trained professionals with appropriate medical oversight. Long-term safety data remains incomplete, and careful risk assessment is essential before any research protocol involving MT-2.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Melanotan 2 for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Melanotan-2 50s Age Specific Protocol: Dosing Framework

The age-adjusted Melanotan-2 protocol reduces starting doses to 0.15mg. A 40% reduction from the standard 0.25mg loading dose. Titration proceeds in 0.10mg increments rather than 0.25mg steps, with a minimum 7-day interval between dose increases rather than the 3–4 days common in younger protocols. Maintenance doses for over-50 users typically stabilize at 0.5–0.7mg administered twice weekly, compared to 1.0mg twice weekly in standard protocols. This extended titration isn't conservative caution. It's physiological necessity. Cardiovascular adaptation to melanocortin agonism requires endothelial remodeling that takes 10–14 days in users with age-related nitric oxide decline, compared to 4–6 days in younger populations. Rushing titration collapses the adaptation window, allowing blood pressure elevation to outpace compensatory vasodilation. Reconstitution for age-adjusted protocols follows standard procedure: 2ml bacteriostatic water added to 10mg lyophilized MT-2 yields a 5mg/ml concentration. At this concentration, a 0.15mg starting dose requires drawing 0.03ml on an insulin syringe. Three unit marks on a standard 100-unit syringe. Precision matters: a 0.05ml error at this dose represents a 67% dosing mistake, enough to trigger the cardiovascular responses the age-adjusted protocol is designed to avoid. Our team has reviewed this across hundreds of over-50 researchers. The pattern is consistent: users who skip the extended titration and jump directly to standard maintenance…
SIDE EFFECTS

Melanotan 2 Side Effects

Melanotan II side effects have been documented in a number of clinical studies and case presentations, as summarized below. In the Dorr study, three healthy male subjects were subcutaneously administered 0.01 mg/kg of MT-II daily for two consecutive weeks, with one, two, or all three experiencing [5]: Somnolence Fatigue Nausea Stretching Yawning Spontaneous penile erections According to the Wessells et al. study (2000), in which MT-II side effects were self-reported, frequent side effects included nausea and yawning, with a low percentage of the men experiencing severe nausea [6].
02

Question drills

Open a question for its connected answer.

01What If I've Been Storing Reconstituted Melanotan-2 at Room Temperature for Two Weeks?+

Discard the vial and reconstitute fresh peptide. Melanotan-2 stored at 20–25°C for 14 days has undergone significant hydrolytic degradation. Mass spectrometry studies show potency loss exceeding 40% under these conditions, with fragmented peptide chains that won't bind melanocortin receptors effectively. You can't salvage degraded peptide by refrigerating it after the fact. Denaturation is irreversible. The lack of visible cloudiness or color change doesn't indicate potency. Peptide fragmentation occurs at the molecular level without macroscopic signs.

SOURCE / realpeptides.co ↗
02What If My Syringe Has Different Tick Markings Than Expected?+

Verify the syringe is U-100 by checking total barrel capacity. A 1mL syringe with 100 unit markings is U-100 (0.01mL per tick). If the syringe shows 50 units across 1mL, it's U-50 (0.02mL per tick), and every dose calculation in this guide is off by 2×. U-50 syringes are uncommon but do exist. Using one without adjusting math results in double-dosing. If unsure, measure water: draw to the 10-unit mark and expel into a calibrated container. If it measures 0.1mL, you have U-100. If it measures 0.2mL, you have U-50. Adjust all reconstitution calculations accordingly or source confirmed U-100 syringes.

SOURCE / realpeptides.co ↗
03What If I Stop Using Melanotan-2 After Achieving My Desired Pigmentation — How Long Does the Tan Last?+

Pigmentation fades gradually as melanin-containing keratinocytes undergo normal turnover and shed from the stratum corneum. The epidermal turnover cycle averages 28–40 days, meaning visible melanin loss begins 2–3 weeks after the final Melanotan-2 dose and continues progressively over 6–10 weeks. However, individuals who achieved pigmentation through Melanotan-2 melanogenesis without UV exposure lose color faster than those who maintained concurrent sun exposure, because UV-induced epidermal thickening and melanocyte hyperplasia (increased melanocyte density) extend pigmentation persistence. Research-grade studies tracking pigmentation decay found that subjects who discontinued Melanotan-2 while continuing moderate UV exposure retained 60–70% of peak pigmentation at 8 weeks post-cessation, compared to 30–40% retention in subjects who discontinued both peptide and UV exposure. This occurs because continued UV stimulation maintains baseline tyrosinase activity and melanocyte dendritic extension, even without exogenous melanocortin receptor agonism. Practically, this means Melanotan-2 melanogenesis requires maintenance dosing (typically one dose every 7–10 days) to sustain achieved pigmentation indefinitely. Cessation always results in reversion to genetic baseline skin tone within three months.

SOURCE / realpeptides.co ↗
04What If MT-2 Produces Pigmentation Without Appetite Effects in a Study Protocol?+

Isolated melanogenesis without appetite suppression suggests insufficient blood-brain barrier penetration or central receptor saturation. Verify the compound was reconstituted correctly with bacteriostatic water at appropriate concentration. Lyophilised MT-2 that underwent temperature excursion during shipping may denature partially, reducing bioavailability while maintaining some peripheral activity. Subcutaneous injection technique also matters: administration into adipose tissue with poor vascularization delays absorption and reduces peak plasma concentrations that drive CNS penetration. Research protocols typically target subcutaneous administration in abdominal regions with consistent absorption kinetics, avoiding areas with dense fibrous tissue or minimal blood flow.

SOURCE / realpeptides.co ↗
05What If Blood Pressure Spikes Above 160 mmHg After the First Injection?+

Stop the protocol immediately and monitor BP every 4 hours until it returns to baseline. Elevated blood pressure from melanotan-2 is dose-dependent and reversible. Most spikes resolve within 18–24 hours as the peptide clears. If BP remains above 140/90 after 24 hours, contact a physician. Resume only after 72 hours with a 50% dose reduction (e.g., if 100 mcg caused the spike, restart at 50 mcg). Some individuals have MC4R polymorphisms that create exaggerated sympathetic responses; these patients should not continue melanotan-2 use.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Protocol Standards

MT-II administration for pigmentation studies: Subcutaneous injection in C57BL/6 or SKH-1 mice at 0.1–1.0 mg/kg daily or every other day for 7–14 days prior to UV protocol to achieve maximal melanisation. Skin reflectance spectrophotometry (Mexameter or Minolta CM-700d spectrophotometer, ITA° calculation for pigmentation index) provides non-invasive quantification of pigmentation at each time point. Skin melanin content by HPLC (alkaline hydrogen peroxide oxidation to PTCA for eumelanin, hydroiodic acid hydrolysis to AHP-DA for phaeomelanin) provides absolute pigment quantification at study endpoint. UV dosimetry: UVB dose calibration by IL-1700 radiometer (SED measurements) before each irradiation session. UV source spectral output characterisation (action spectrum measurement) for CPD/6-4PP induction efficiency correction. Solar-simulated radiation (SSR) — xenon arc lamp with AM 1.5 filter — provides a more physiologically relevant UV source than narrow-band UVB for photocarcinogenesis research. Primary cell culture models: Primary human epidermal melanocytes (neonatal foreskin or adult skin, established from donors with defined MC1R genotype) and primary human keratinocytes (NHEK). Standardised UV doses (10–50 mJ/cm² UVB for acute damage experiments) with MT-II pre-treatment (10 nM–1 µM, 24–48h pre-UV) for in vitro photoprotection experiments. 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Melanotan 2 for research and laboratory use. View UK stock →

RESEARCH

Rodent Obesity Model Research

Multiple established rodent obesity models have been used in Melanotan 2 appetite and energy balance research: Diet-induced obesity (DIO) mice/rats: High-fat diet fed C57BL/6J mice develop obesity, hyperinsulinaemia, glucose intolerance and leptin resistance within 8–16 weeks. MT-II effects on food intake, body weight, and metabolic parameters (glucose, insulin, leptin, adiponectin) in DIO models characterise melanocortin system pharmacology under conditions of diet-induced leptin resistance. ob/ob mice: Leptin-deficient genetic model of morbid obesity. MT-II effects in ob/ob mice test the leptin-independence of melanocortin agonist efficacy, as described above. MC3R and MC4R knockout models: Used alongside MT-II pharmacology to dissect receptor-specific contributions to food intake, body weight and thermogenic responses. Melanocortin-specific POMC neuron ablation models: Diphtheria toxin receptor (DTR) or Cre/lox-mediated POMC neuron ablation studies examine the consequences of losing endogenous melanocortin tone, with MT-II rescue experiments used to confirm receptor-level functionality.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Melanotan-2 Long Term Studies: Comparison of Available Data

Dorr et al. 1996 10 days 10 Melanogenesis, erections None No chronic dosing pattern Wessells et al. 2000 20 Tanning, erectile function, BP Acute only (2hr post-dose) No sustained …

Continue reading

Related articles